BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26955282)

  • 1. Neoadjuvant chemoradiotherapy or chemotherapy followed by surgery is superior to that followed by definitive chemoradiation or radiotherapy in stage IIIA (N2) nonsmall-cell lung cancer: a meta-analysis and system review.
    Xu XL; Dan L; Chen W; Zhu SM; Mao WM
    Onco Targets Ther; 2016; 9():845-53. PubMed ID: 26955282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.
    Xu YP; Li B; Xu XL; Mao WM
    Medicine (Baltimore); 2015 Jun; 94(23):e879. PubMed ID: 26061306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society).
    Couñago F; Rodriguez de Dios N; Montemuiño S; Jové-Teixidó J; Martin M; Calvo-Crespo P; López-Mata M; Samper-Ots MP; López-Guerra JL; García-Cañibano T; Díaz-Díaz V; de Ingunza-Barón L; Murcia-Mejía M; Alcántara P; Corona J; Puertas MM; Chust M; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Thuissard IJ; Sanz-Rosa D; Taboada B
    Lung Cancer; 2018 Apr; 118():119-127. PubMed ID: 29571989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgery after chemoradiotherapy in patients with stage III (N2 or N3, excluding T4) non-small-cell lung cancer: a systematic review.
    Swaminath A; Vella ET; Ramchandar K; Robinson A; Simone C; Sun A; Ung YC; Yasufuku K; Ellis PM
    Curr Oncol; 2019 Jun; 26(3):e398-e404. PubMed ID: 31285684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemoradiation and surgery improves survival outcomes compared with definitive chemoradiation in the treatment of stage IIIA N2 non-small-cell lung cancer.
    Darling GE; Li F; Patsios D; Massey C; Wallis AG; Coate L; Keshavjee S; Pierre A; De Perrot M; Yasufuku K; Cypel M; Waddell T
    Eur J Cardiothorac Surg; 2015 Nov; 48(5):684-90; discussion 690. PubMed ID: 25567960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy plus radiotherapy is superior to chemotherapy following surgical treatment of stage IIIA N2 non-small-cell lung cancer.
    Lei T; Xu XL; Chen W; Xu YP; Mao WM
    Onco Targets Ther; 2016; 9():921-8. PubMed ID: 26966380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer.
    Shah AA; Berry MF; Tzao C; Gandhi M; Worni M; Pietrobon R; D'Amico TA
    Ann Thorac Surg; 2012 Jun; 93(6):1807-12. PubMed ID: 22632486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.
    Kokka F; Bryant A; Brockbank E; Powell M; Oram D
    Cochrane Database Syst Rev; 2015 Apr; (4):CD010260. PubMed ID: 25847525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction chemoradiotherapy versus induction chemotherapy for potentially resectable stage IIIA (N2) non-small cell lung cancer: a systematic review and meta-analysis.
    Tong S; Qin Z; Wan M; Zhang L; Cui Y; Yao Y
    J Thorac Dis; 2018 Apr; 10(4):2428-2436. PubMed ID: 29850149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.
    Koshy M; Fedewa SA; Malik R; Ferguson MK; Vigneswaran WT; Feldman L; Howard A; Abdelhady K; Weichselbaum RR; Virgo KS
    J Thorac Oncol; 2013 Jul; 8(7):915-22. PubMed ID: 23608815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk associated with bilobectomy after neoadjuvant concurrent chemoradiotherapy for stage IIIA-N2 non-small-cell lung cancer.
    Cho JH; Kim J; Kim K; Shim YM; Kim HK; Choi YS
    World J Surg; 2012 May; 36(5):1199-1205. PubMed ID: 22374538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidisciplinary therapy of stage IIIA non-small-cell lung cancer: long-term outcome of chemoradiation with or without surgery.
    Aggarwal C; Li L; Borghaei H; Mehra R; Somaiah N; Turaka A; Langer CJ; Simon GR
    Cancer Control; 2014 Jan; 21(1):57-62. PubMed ID: 24357742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).
    Couñago F; Montemuiño S; Martin M; Taboada B; Calvo-Crespo P; Samper-Ots MP; Alcántara P; Corona J; López-Guerra JL; Murcia-Mejía M; López-Mata M; Jové-Teixidó J; Chust M; Díaz-Díaz V; de Ingunza-Barón L; García-Cañibano T; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Puertas MM; Thuissard IJ; Sanz-Rosa D; de Dios NR
    Clin Transl Oncol; 2019 Jun; 21(6):735-744. PubMed ID: 30430394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer.
    Yang CF; Adil SM; Anderson KL; Meyerhoff RR; Turley RS; Hartwig MG; Harpole DH; Tong BC; Onaitis MW; D'Amico TA; Berry MF
    Eur J Cardiothorac Surg; 2016 Jun; 49(6):1607-13. PubMed ID: 26719403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgery for early stage non-small cell lung cancer.
    Manser R; Wright G; Hart D; Byrnes G; Campbell DA
    Cochrane Database Syst Rev; 2005 Jan; 2005(1):CD004699. PubMed ID: 15674959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of stage IIIA non-small cell lung cancer by thoracic surgeons in North America.
    Veeramachaneni NK; Feins RH; Stephenson BJ; Edwards LJ; Fernandez FG
    Ann Thorac Surg; 2012 Sep; 94(3):922-6; discussion 926-8. PubMed ID: 22742842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
    Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
    J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
    Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemoradiotherapy followed by surgery for stage IIIa and IIIb non-small-cell lung cancer (NSCLC): is it still justified?
    Mirimanoff RO
    Chin Clin Oncol; 2015 Dec; 4(4):49. PubMed ID: 26730761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of surgery in N2 NSCLC: pros.
    Shien K; Toyooka S
    Jpn J Clin Oncol; 2016 Dec; 46(12):1168-1173. PubMed ID: 27655902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.